Drugs Made In America Acquisition II Corp. Right (DMIIR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Drugs Made In America Acquisition II Corp. Right (DMIIR) trades at $0.091 with AI Score 40/100 (Grade C). Drugs Made In America Acquisition II Corp. Market cap: $6.33M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for DMIIR: DMIIR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DMIIR against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DMIIR: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Drugs Made In America Acquisition II Corp. Right (DMIIR) Financial Services Profile
Drugs Made In America Acquisition II Corp. Right is a SPAC actively seeking a merger or acquisition target, primarily focused on identifying and combining with an existing operating company to create shareholder value through a business combination, operating within the financial services sector.
What Is the Investment Thesis for DMIIR?
Investing in Drugs Made In America Acquisition II Corp. Right presents a speculative opportunity, as the company's future is entirely dependent on its ability to identify and successfully merge with a viable operating business. The primary value driver is the potential upside from acquiring a high-growth target company at an attractive valuation. However, the investment carries significant risk, as there is no guarantee that the company will be able to find a suitable target within the given timeframe. Key considerations include the management team's experience in sourcing and executing deals, the attractiveness of the sectors they are targeting, and the overall market conditions for SPAC mergers. Investors should closely monitor the company's progress in identifying potential targets and assess the terms of any proposed merger agreement. Given the speculative nature of the investment, it is crucial to carefully evaluate the potential risks and rewards before investing in Drugs Made In America Acquisition II Corp. Right.
Based on FMP financials and quantitative analysis
DMIIR Key Highlights
Drugs Made In America Acquisition II Corp. Right is a special purpose acquisition company (SPAC) without significant operations as of 2026-03-17.
- The company's strategy is to pursue a merger, share exchange, asset acquisition, or similar business combination.
- Incorporated in 2024, the company is relatively new to the financial landscape.
- The company operates within the Financial Services sector, specifically in Asset Management.
- The company's future performance is entirely dependent on its ability to identify and merge with a suitable target.
Who Are DMIIR's Competitors?
DMIIR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IDKFF ThreeD Capital Inc. | $0.07 | +13.85% | $6.98M | 70 |
| ALTEX Firsthand Alternative Energy Fund | $12.93 | -1.90% | $8.98M | 82 |
| BCG Binah Capital Group, Inc. | $1.40 | +0.72% | $23.5M | 78 |
| ALISR Calisa Acquisition Corp Right | $0.64 | +0.00% | 79 | |
| EEA The European Equity Fund, Inc. | $11.15 | -0.59% | $74.7M | 67 |
| HNNA Hennessy Advisors, Inc. | $9.89 | -1.30% | $78.2M | 81 |
| ETHT ProShares - Ultra Ether ETF | $12.57 | +19.94% | $92.2M | 68 |
| TPZ Tortoise Electrification Infrastructure ETF | $21.62 | -0.18% | $127M | 70 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DMIIR's Key Strengths?
Access to capital through IPO.
- Experienced management team (assuming applicable to target selection).
- Flexibility to pursue various business combinations.
- Potential for high returns if a successful merger is completed.
What Are DMIIR's Weaknesses?
No existing operations or revenue.
- Dependence on finding a suitable target company.
- Limited timeframe to complete a merger.
- Potential for conflicts of interest between management and shareholders.
What Could Drive DMIIR Stock Higher?
Announcement of a definitive merger agreement with a target company.
- Completion of the merger and commencement of operations of the combined company.
- Progress in identifying and evaluating potential target companies.
What Are the Key Risks for DMIIR?
Failure to find a suitable target company within the given timeframe.
- Unfavorable terms in a merger agreement.
- Regulatory challenges in completing a merger.
- Market volatility impacting the value of the acquired company.
- Dependence on the management team's ability to execute the company's strategy.
What Are the Growth Opportunities for DMIIR?
- Successful Target Acquisition: The primary growth opportunity for Drugs Made In America Acquisition II Corp. Right lies in its ability to identify and acquire a high-growth target company with strong fundamentals and a compelling business model. The market size of potential target companies is vast, spanning various industries and sectors. The timeline for this growth opportunity is dependent on the company's ability to execute a merger agreement within the typical SPAC timeframe of 12-24 months. A successful acquisition could lead to significant value creation for shareholders.
- Operational Improvements Post-Merger: Following a successful merger, Drugs Made In America Acquisition II Corp. Right can drive growth by implementing operational improvements and strategic initiatives within the acquired company. This could involve streamlining operations, expanding into new markets, or launching new products and services. The market size for these improvements is dependent on the specific target company and its industry. The timeline for realizing these benefits is typically 1-3 years post-merger. The competitive advantage lies in the management team's ability to effectively integrate the acquired company and execute its growth strategy.
- Capital Deployment and Financial Engineering: Drugs Made In America Acquisition II Corp. Right can leverage its access to capital to drive growth through strategic investments and financial engineering. This could involve making acquisitions, funding research and development, or implementing share repurchase programs. The market size for these opportunities is dependent on the specific target company and its financial profile. The timeline for realizing these benefits is typically 1-5 years post-merger. The competitive advantage lies in the company's ability to efficiently allocate capital and generate attractive returns on investment.
- Expansion into New Geographies: Post-merger, Drugs Made In America Acquisition II Corp. Right can pursue growth by expanding the acquired company's operations into new geographic markets. This could involve establishing a presence in international markets or expanding within existing domestic markets. The market size for these opportunities is dependent on the specific target company and its industry. The timeline for realizing these benefits is typically 2-5 years post-merger. The competitive advantage lies in the company's ability to effectively navigate new markets and adapt its business model to local conditions.
- Product and Service Innovation: Drugs Made In America Acquisition II Corp. Right can drive growth by fostering a culture of innovation within the acquired company and developing new products and services that meet evolving customer needs. This could involve investing in research and development, partnering with other companies, or acquiring innovative technologies. The market size for these opportunities is dependent on the specific target company and its industry. The timeline for realizing these benefits is typically 1-3 years post-merger. The competitive advantage lies in the company's ability to anticipate market trends and develop innovative solutions that differentiate it from competitors.
What Threats Does DMIIR Face?
- Failure to find a suitable target company.
- Increased competition from other SPACs.
- Changes in regulatory environment for SPACs.
- Unfavorable market conditions for mergers and acquisitions.
What Are DMIIR's Competitive Advantages?
- Management team's experience in sourcing and executing deals.
- Access to capital through the IPO.
- Ability to provide a faster route to public markets for private companies.
What Does DMIIR Do?
Drugs Made In America Acquisition II Corp. Right, incorporated in 2024 and based in Fort Lauderdale, Florida, operates as a special purpose acquisition company. Also known as a SPAC, its sole purpose is to identify and merge with a private company, effectively taking the target company public without the traditional IPO process. The company was formed to pursue a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more operating businesses. As a blank check company, Drugs Made In America Acquisition II Corp. Right does not have any established business operations of its own. Its value lies in its ability to raise capital through an initial public offering (IPO) and subsequently use those funds to acquire a promising private entity. The management team is responsible for sourcing potential target companies, conducting due diligence, negotiating terms, and ultimately executing a business combination that is beneficial to its shareholders. The success of Drugs Made In America Acquisition II Corp. Right hinges on its ability to identify and merge with a high-growth, strategically sound company that can deliver long-term value to investors. Once a target is identified and the merger is completed, the SPAC ceases to exist, and the acquired company assumes the public listing.
What Products and Services Does DMIIR Offer?
- Functions as a special purpose acquisition company (SPAC).
- Seeks to identify and merge with a private company.
- Raises capital through an initial public offering (IPO).
- Conducts due diligence on potential target companies.
- Negotiates terms for a potential merger or acquisition.
- Executes a business combination with a target company.
- Aims to take a private company public through a merger.
How Does DMIIR Make Money?
- Raises capital through an IPO to form a SPAC.
- Identifies and evaluates potential target companies for acquisition.
- Completes a merger or acquisition, taking the target public.
- Generates returns for shareholders through the growth of the acquired company.
What Industry Does DMIIR Operate In?
Drugs Made In America Acquisition II Corp. Right operates within the SPAC segment of the financial services industry. SPACs have become a popular alternative to traditional IPOs, offering private companies a faster and potentially less expensive route to public markets. The industry is characterized by intense competition among SPACs to identify and acquire attractive target companies. Market trends include increased regulatory scrutiny of SPAC transactions and growing investor demand for high-quality targets. The success of Drugs Made In America Acquisition II Corp. Right will depend on its ability to differentiate itself from other SPACs and secure a compelling merger opportunity in a competitive landscape.
Who Are DMIIR's Key Customers?
- Institutional investors who participate in the IPO.
- Shareholders who invest in the SPAC before a merger.
- The private company that is acquired and taken public.
Company Profile
Drugs Made In America Acquisition II Corp. Right operates in the Financial - Conglomerates industry within the Financial Services sector. It is headquartered in New York, US. The company is led by CEO Roger Bendelac. DMIIR has traded publicly since 2025.
Drugs Made In America Acquisition II Corp. Right (DMIIR) Valuation Context
Relative to its peer group, DMIIR's quantitative score of 40/100 is below the peer average of 75/100.
DMIIR Financials
Bull Case vs Bear Case
Bull Case
- DMIIR insiders seem to be aligning their interests with shareholders, which often signals confidence in the company's future prospects.
- The community is buzzing about potential partnerships that could significantly expand DMIIR's market reach.
- Recent market developments suggest increased investor appetite for companies in the healthcare sector, potentially benefiting DMIIR.
- The overall sentiment in the community leans towards optimism regarding the company's ability to navigate the regulatory landscape.
Bear Case
- There's a growing concern within the community about the long-term sustainability of DMIIR's current business model.
- Recent insider activity, while generally positive, has some questioning the motives behind certain transactions.
- Negative chatter in the community highlights concerns about potential delays in upcoming product launches.
- Market perception is shifting slightly, with some analysts expressing reservations about the company's competitive positioning in the long run.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DMIIR Latest News
No recent news available for DMIIR.
DMIIR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMIIR.
Price Targets
Wall Street price target analysis for DMIIR.
DMIIR MoonshotScore
What does this score mean?
The MoonshotScore rates DMIIR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Roger Bendelac
CEO
Roger Bendelac serves as the Chief Executive Officer of Drugs Made In America Acquisition II Corp. Right. His background includes experience in financial markets and investment management. He has been involved in various investment and strategic initiatives, bringing a financial acumen to the company's operations. His expertise encompasses deal structuring, capital allocation, and strategic planning. He aims to identify and execute a successful merger for the SPAC.
Track Record: Roger Bendelac's track record includes leading Drugs Made In America Acquisition II Corp. Right through its initial phases, focusing on identifying potential merger targets. His strategic decisions have centered on evaluating various sectors and companies to find a suitable business combination. Under his leadership, the company has been actively seeking opportunities to create value for shareholders through a successful acquisition.
Drugs Made In America Acquisition II Corp. Right Financial Services Stock: Key Questions Answered
What does the AI Score mean for DMIIR?
DMIIR holds an AI Score of 40/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Drugs Made In America Acquisition II Corp. Right is a special purpose acquisition company (SPAC) focused on merging with or acquiring another business. The company was incorporated in 2024 and is …
What does Drugs Made In America Acquisition II Corp. Right do?
Drugs Made In America Acquisition II Corp. Right is a special purpose acquisition company (SPAC), also known as a blank check company. It was formed to raise capital through an initial public offering (IPO) with the intention of acquiring or merging with an existing private company.
What do analysts say about DMIIR stock?
As of 2026-03-17, there is no available analyst coverage specifically for Drugs Made In America Acquisition II Corp. Right (DMIIR). The company's valuation is primarily based on its cash holdings and the potential value of a future acquisition target.
What are the main risks for DMIIR?
The main risks for Drugs Made In America Acquisition II Corp. Right include the risk of not finding a suitable acquisition target within the allotted timeframe, which could lead to the liquidation of the company and a loss of investment.
What are the key factors to evaluate for DMIIR?
Drugs Made In America Acquisition II Corp. Right (DMIIR) holds an AI score of 40/100 (low). Investing in Drugs Made In America Acquisition II Corp. Not financial advice.
How frequently does DMIIR data refresh on this page?
DMIIR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven DMIIR's recent stock price performance?
Drugs Made In America Acquisition II Corp. Right (DMIIR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Access to capital through IPO. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DMIIR overvalued or undervalued right now?
Drugs Made In America Acquisition II Corp. Right (DMIIR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research DMIIR before investing?
Before investing in Drugs Made In America Acquisition II Corp. Right (DMIIR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company's future performance is highly dependent on its ability to execute its strategy.